Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the management of mild to moderate dementia associated with Parkinson's disease.
Amarin has developed a Rivastigmine TDS using its liquid-in-liquid adhesive technology, and concluded a Phase I study using Exelon Patch as comparator in 2011.
A patent application was filed in Europe, USA, Canada, Brazil, Mexico and Argentina.
The product has been licensed to Asofarma (Argentine) under non-exclusive terms for Argentine and Brazil.
Amarin is seeking to license this product for USA, Europe and other territories.
Mr. Sergio Lucero
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.View profile
Clients in focus...